摘要
目的：研究应用西格列汀对糖耐量减低（IGT）人群进行药物干预对2型糖尿病发病率的影响。方法：选取确诊为IGT患者共111例。年龄40～75岁，初访时随机分成饮食运动组、阿卡波糖组和西格列汀组。对所有患者随访12个月。比较分析3组患者在预防糖尿病的发生发展、减少并发症等方面的差异性。结果：初访时3组基线资料无统计学差异。12个月后，饮食运动组空腹血糖（FBG）轻度升高，但餐后2h血糖（2hPBG）轻度下降，糖尿病的发病率为10．5％：西格列汀组和阿卡波糖组FBG及2hPBG均显著下降．糖尿病的发病率分别为2．5％和3．3％：药物干预组平均FBG与饮食运动组比较差异有显著性：而西格列汀组与阿卡波糖组比较在减少糖尿病发病率和低血糖事件方面差异均无显著性。结论：在IGT干预治疗中，西格列汀可达到显著减少糖尿病发生的效果。
Objective To assess the effect of Sitagliptin on subjects with impaired glucose tolerance （IGT） to the incidence of type 2 diabetic mellitus （T2DM）. Methods 111 subjects aged between 40 to 75 years old with IGT were collected. The subjects were randomly divided into diet plus exercise group, Acarbose group, Sitagliptin group. The follow-up time was 12 months. The difference of diabetes occurence prevention, and the complication reduction were compared and analyzed among three groups. Results There was no statistical difference among the baseline data among three groups in first visting. After 12 months, the fasting blood-glucose （FBG） in the diet plus exercise group mildly increased, while the 2h postprandial blood-glucose （2hPBG） mildly decreased, and the annual diabetes incidence was 10.5%. Both FBG and 2hPBG in Sitagliptin and Acarbose group all significantly decreased, the diabetes incidence decreased to 2.5% in Sitagliptin group, and 3.3% in Acarbose group respectively. There was significantly difference between the medication intervention group and the diet plus exercise group. While there was no significant difference between the Sitagliptin group and the Acarbose group in reducing the incidence of diabetes and hypoglycemia. Conclusion The pharmacological interventions with Sitagliptin would significantly decrease the diabetes incidence in IGT population.
出处
《实用医学杂志》
CAS
北大核心
2013年第21期3578-3580,共3页
The Journal of Practical Medicine
基金
广东省医学科学技术研究基金立项项目(编号:A2011294)
关键词
糖尿病
2型
糖耐量减低
西格列汀
干预性研究
Diabetes mellitus, type 2
Impaired glucose tolerance
Sitagliptin
Intervention studies
